Experiment 1041104
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | COONLEY,CJ: WARRELL JR,RP: YOUNG,CW:. (1983). PHASE I TRIAL OF HOMOHARRINGTONINE ADMINISTERED AS A 5-DAY CONTINUOUS INFUSION.. 67(7/8) |
| Amount utilized | |
| Compound isolated | |
| Disease | A PHASE I STUDY IN 31 PATIENTS WITH THE TITLE COMPOUND ADMINISTERED AS A CONTINUOUS INFUSION FOR 5 DAYS IN PATIENTS WITH ADVANCED CANCER. MYELOSUPPRESSION (BOTH LEUKOPENIA AND THROMBOCYTOPENIA) WAS THE DOSE-LIMITING TOXIC REACTION. DOSES RANGED FROM 0.2 TO 3.75 MG/SQ.M/DAY. PLATELET RECOVERY WAS DELAYED IN 5 PATIENTS, MEDIAN TIME TO PLATELET NADIR WAS 31 DAYS IN PATIENTS TREATED WITH THE HIGHEST DOSE LEVEL. SINUS TACHYCARDIA OCCURRED FREQUENTLY, BUT THE RELATIONSHIP OF THIS EFFECT TO DRUG ADMINISTRATION WAS UNCERTAIN. SERIOUS CARDIAC ARRHYTHMIAS AND HYPOTENSION WERE NOT OBSERVED USING THIS SCHEDULE. IT WAS CONCLUDED THAT THE TITLE COMPOUND CAN BE SAFELY ADMINISTERED AS A CONTINUOUS INFUSION. A DAILY DOSE OF 3.25 MG/SQ.M/DAY IS RECOMMENDED FOR PHASE II STUDIES. |
| Dose amount | 3.75 MG |
| Number | 1 |
| Qualitative result | . |
| Animal | HUMAN ADULT |
| Per unit | SQ M BODY SURFACE |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |